Table 1.
Donor and Recipient Characteristics
| Donor rs738409 CC | Donor rs738409 GC or GG | ||
|---|---|---|---|
| n = 57 | n = 44 | P | |
| Recipient characteristics | |||
| Recipient rs738409 | 0.95 | ||
| CC | 32 (56%) | 25 (57%) | |
| GC/GG | 25 (43%) | 19 (43%) | |
| Age, years | 56 (6) | 53 (6) | 0.01 |
| Gender | 0.68 | ||
| Male | 42/57 (74%) | 34/44 (77%) | |
| Female | 15/57 (26%) | 10/44 (23%) | |
| Ethnicity | 0.93 | ||
| White | 46/57 (81%) | 34/44 (77%) | |
| Black | 6/57 (11%) | 6/44 (14%) | |
| Hispanic | 3/57 (5%) | 3/44 (7%) | |
| Asian | 2/57 (3%) | 1/44 (2%) | |
| Diabetes (pre-OLT) | 15/57 (26.%) | 10/44 (23%) | 0.68 |
| MELD score (pre-OLT) | 21 (10) | 20 (10) | 0.86 |
| Alcoholic cirrhosis | 18/57 (32%) | 5/44 (12%) | 0.02 |
| Hepatocellular carcinoma | 15/57 (26%) | 16/44 (36%) | 0.28 |
| Simultaneous liver kidney | 3/57 (5%) | 6/44 (14%) | 0.14 |
| Hepatitis C genotype | 0.91 | ||
| 1 | 44/57 (77%) | 35/44 (80%) | |
| 2 | 6/57 (11%) | 3/44 (7%) | |
| 3 | 4/57 (7%) | 4/44 (9%) | |
| Indeterminant/missing | 3/57 (5%) | 2/44 (4%) | |
| Log viral load (Pre-OLT) | 5.6 (5.0–6.3) (n 5 56) | 5.9 (4.9–6.5) (n 5 40) | 0.35 |
| Donor characteristics | |||
| Age, years | 35 (13) | 32 (12) | 0.14 |
| Ethnicity | 0.11 | ||
| White | 46/57 (80%) | 30/44 (68%) | |
| Black | 8/57 (14%) | 6/44(14%) | |
| Hispanic | 1/57(2%) | 7/44(16%) | |
| Asian | 1/57 (2%) | 1 /44(2%) | |
| Other | 1/57(2%) | ||
| Diabetes | 0/57 (0%) | 1/44 (2%) | 0.25 |
| Cause of death | 0.65 | ||
| Anorexia | 15/57 (26%) | 7/44 (16%) | |
| CVA/stroke | 13/57 (23%) | 12/44 (27%) | |
| Head trauma | 27/57 (47%) | 23/44 (52%) | |
| Other | 2/57 (4%) | 2/44 (5%) | |
| Gender | 0.98 | ||
| Male | 39/57 (68%) | 30/44(68%) | |
| Female | 18/57 (32%) | 14/44 (32%) | |
| Height, cm | 173 (11) | 177 (11) | 0.13 |
| AST, IU/L | 42 (31-99) | 50 (29-108) | 0.69 |
| Cold ischemic time | 378 (114) | 379 (149) | 0.99 |
| Warm ischemic time | 52 (46-62) | 53 (47-64) | 0.38 |
| Early allograft dysfunction | |||
| Olthoff et al. | 11/57 (19%) | 8/44 (18%) | 0.89 |
| Modified Deschenes et al. | 5/57 (9%) | 1/43 (2%) | 0.17 |
| Wagener et al. | 7/57 (12%) | 12/44 (27%) | 0.056 |
| Immunosuppressant | |||
| Predominant | 0.27 | ||
| Tacrolimus | 47/57 (82%) | 32/44 (73%) | |
| Cyclosporin | 9/57 (16%) | 12/44 (27%) | |
| Rapamycin | 1/57 (2%) | ||
| Mycophenolate Mofetil >6 mo | 34/57 (60%) | 22/44 (50%) | 0.33 |
| Prednisone > 6mo | 17/57 (30%) | 11/44 (25%) | 0.59 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CVA, cerebrovascular accident; MELD, Model for End-Stage Liver Disease; OLT, orthotopic liver transplantation.
Olthoff et al.'s definition: either a total bilirubin level >10 mg/dL or an INR >1.6 on postoperative day 7 or an AST or ALT level >2000 IU/L within the first 7 days.
Modified Deschenes et al.'s definition: a peak total bilirubin level >10 mg/dL on postoperative days 2 to 7.
Wagener et al.'s definition: MELD score >18.9 on postoperative day 5.
Categorical variables are expressed as n (%) and compared by chi-square test. Continuous parametric variables are expressed as mean (standard deviation) and compared by t test. Continuous nonparametric variables are expressed as median (interquartile range) and compared by Wilcoxon two-sample test. N557 in the donor CC group and n = 44 in the donor GC/GG group unless otherwise specified.